ERBB2 and breast carcinoma: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR<sup>+</sup>/HER2<sup>-</sup>) early breast cancer (EBC) patients face long-term recurrence risk despite standard treatment.